Medivir reveals final ASPIRE data for hep C protease inhibitor
This article was originally published in Scrip
Executive Summary
Medivir has reported the final results of its Phase IIb ASPIRE study, investigating its hepatitis C treatment, TMC435, which confirmed that the product significantly improves viral cure rates in patients who have failed prior treatment for the infection. TMC435 is a once-daily, oral hepatitis C virus protease inhibitor, which is being developed jointly with Tibotec Pharmaceuticals (J&J). The product is currently in Phase III, with three global pivotal studies ongoing.